Stockscreener 앱 받기
58.20
0.00%
0.00
시간 외 거래:
57.50
-0.70
-1.20%
Scholar Rock Holding Corp 주식(SRRK)의 최신 뉴스
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission - Reuters
Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus - Kalkine Media
Scholar Rock advances apitegromab FDA review - grafa.com
Scholar Rock removes Catalent facility from SMA drug application By Investing.com - Investing.com Canada
Scholar Rock is prepared to launch its SMA drug if FDA approves by Sept. 30 - Stock Titan
Eagle Health Investments LP Invests $30.54 Million in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Scholar Rock Holding (SRRK) After Apitegromab Progress Is The Stock Already Fully Valued - Sahm
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab - MarketBeat
How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review - simplywall.st
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks? - Yahoo Finance
Redmile Group (SRRK) updates Scholar Rock stake to 3.6% of common stock - Stock Titan
12 New Hires Receive 51,947 Scholar Rock Equity Awards - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
Scholar Rock (SRRK) Stock Looks Priced At A Premium Today - simplywall.st
SRRK Maintains by JP Morgan -- Price Target Raised to $63.00 - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares - Stock Titan
SRRK Stock Prediction: Huge SMA Drug Launch Breakthrough? (2026 Alert) The Rock (yAPbDwyblt) - Mshale
Scholar Rock at canaccord growth conference: approval path narrows By Investing.com - Investing.com Canada
Scholar Rock at canaccord growth conference: approval path narrows - Investing.com India
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
Q3 EPS Estimates for Scholar Rock Cut by HC Wainwright - MarketBeat
Scholar Rock: Apitegromab's Approval Is Key, Here's My Take Moscow Victory Day Parade (Ok0Q1xN954) - Mshale
Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Potential 15.51% Upside in the Biotech Arena - DirectorsTalk Interviews
Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
SRRK Reiterated by Wedbush -- Maintains Price Target at $58.00 - GuruFocus
Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush - MarketBeat
H.C. Wainwright reiterates Scholar Rock stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Scholar Rock stock rating at buy - Investing.com
SRRK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $65 - GuruFocus
Scholar Rock Holding Corp (SRRK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SRRK Maintained at Buy by Citigroup -- Price Target Raised to $6 - GuruFocus
Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug - marketscreener.com
Vials for an SMA treatment candidate await packaging as FDA review shifts - Stock Titan
Scholar Rock Q2 Earnings Call Highlights - finance.yahoo.com
SRRK SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag -- Update - marketscreener.com
Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates - marketbeat.com
Scholar Rock files $200 million at-the-market offering prospectus with SEC - Investing.com Nigeria
Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlig - GuruFocus
Earnings call transcript: Scholar Rock tops Q2 2026 EPS view, shares rise premarket - Investing.com
Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlights: Dual Paths to FDA Approval ... - Yahoo Finance
Scholar Rock (SRRK) Nears Approval for First Myostatin Inhibitor Amid High Price-to-Sales Valuation - GuruFocus
Is Scholar Rock Holding Corp (SRRK) Positioned for Success After Q2 Earnings Miss? GF Score: 26/100, EPS at -$0.84 - GuruFocus
Form 8K Scholar Rock Holding Corp For: 6 August By Investing.com - Investing.com Nigeria
Scholar Rock Holding Corp 2Q 2026: Net loss $(215.4M), EPS $(1.67) — 10-Q Summary - TradingView
Scholar Rock (NASDAQ: SRRK) details apitegromab review, $492M cash balance - Stock Titan
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Scholar Rock faces earnings test with FDA decision looming - Investing.com
Scholar Rock faces earnings test with FDA decision looming By Investing.com - Investing.com Nigeria
Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Biotech Giant with 29% Upside Potential - DirectorsTalk Interviews
Sei Investments Co. Grows Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation $SRRK Shares Bought by Janus Henderson Group PLC - MarketBeat
Scholar Rock (SRRK) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Scholar Rock Sets Aug. 12 Webcast From Boston Growth Conference - Stock Titan
ADAR1 Capital Management LLC Grows Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm - Morningstar
0.00%
3.22%
자본화:
|
볼륨(24시간):